Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tunlametinib + Vemurafenib in BRAF V600E NSCLC
NCT05900219Phase 2Not yet recruiting
- Sponsor
- Shanghai KeChow Pharmaceuticals
- Start
- Sep 2023
- Primary completion
- Sep 2025
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of tunlametinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai KeChow Pharmaceuticals. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
tunlametinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05900219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05900219.